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A B S T R A C T
The essential trace element, selenium (Se), is crucial to the brain but it may be potentially neurotoxic, depending
on dosage and speciation; Se has been discussed for decades in relation to Alzheimer's disease (AD).
Selenoprotein P (SELENOP) is a secreted heparin-binding glycoprotein which serves as the main Se transport
protein in mammals. In vivo studies showed that this protein might have additional functions such as a con-
tribution to redox regulation. The current review focuses on recent research on the possible role of SELENOP in
AD pathology, based on model and human studies. The review also brieﬂy summarizes results of epidemiological
studies on Se supplementation in relation to brain diseases, including PREADViSE, EVA, and AIBL. Although
mainly positive eﬀects of Se are assessed in this review, possible detrimental eﬀects of Se supplementation or
exposure, including potential neurotoxicity, are also mentioned. In relation to AD, various roles of SELENOP are
discussed, i.e. as the means of Se delivery to neurons, as an antioxidant, in cytoskeleton assembly, in interaction
with redox-active metals (copper, iron, and mercury) and with misfolded proteins (amyloid-beta and hyper-
phosphorylated tau-protein).
1. Introduction
Selenoprotein P (SELENOP [1], also known as SelP, SePP, SePP1,
and SeP) is one of 25 human selenoproteins [2] containing the 21st
proteinogenic amino acid selenocysteine (Sec). SELENOP is the sole
human selenoprotein that can contain up to ten Sec residues [3,4] and
is considered to be the main selenium (Se) transport protein in mam-
mals [5]. Se is a trace element essential for humans that, while being
crucial to the brain, can also be highly neurotoxic depending on dosage
and speciation [4,6,7]. Although the content of Se in the brain is only
some 2.3% of the total amount of Se in the human body [8], the brain is
highly protected from Se depletion owing to the hierarchical structure
of Se metabolism [9]. The region-speciﬁc pattern for brain Se deposi-
tion has been found using radioactive 75Se-labeled selenite. The brain
uptake of labeled 75Se-selenite was shown to start only after the ap-
pearance of plasma 75Se-SELENOP, diﬀerentiating the brain from other
tissues [10]. Interestingly, with the injection of 75Se-labeled SELENOP,
the accumulation of 75Se in the Se-depleted rat brain two hours later
was ﬁve-times greater (p < 0.05) than in Se-suﬃcient controls [11],
while total body turnover for 75Se was insigniﬁcantly aﬀected by Se
status. Under low Se supply, the brain tends to store Se at a nearly
constant level [12]. Se deprivation causes irreversible damage to neu-
ronal tissue [12,13]. Such hierarchy of Se homeostasis is good evidence
for its essential functions in the brain [14] and SELENOP is thought to
take a central part in maintaining such hierarchy [9]. Indeed, the im-
pairment of brain Se homeostasis or severe Se deﬁciency causes highly
detrimental neurological outcomes and can become lethal in extreme
cases [4,13]. Se seems to be involved in most molecular mechanisms
related to neurodegeneration pathology and speciﬁcally in Alzheimer's
disease (AD); these include redox pathways, myelopathies, signal
transduction and cytoskeleton assembly [15,16].
SELENOP is a potentially multifunctional protein with both
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enzymatic and Se-transport activities that plays a central role in body Se
transport and maintaining tissue Se hierarchy [17]. Plasma/serum SE-
LENOP concentration is therefore considered to be a more accurate
biomarker of Se status than total serum Se or plasma/serum glutathione
peroxidase (GPX3) activity [18,19]. SELENOP plays an import role in
the transport of Se to the brain for the synthesis of essential seleno-
proteins [16] such as GPX and thioredoxin reductase (TrxR) [20].
Currently, SELENOP is considered to be an indicator selenoprotein for
the saturation of Se nutritional requirements [8,21]. However, SE-
LENOP functions are not limited solely to Se transport [19]; it contains
a redox motif and exhibits certain antioxidant properties [12,22] con-
tributing to redox regulation. Experiments with transgenic mice showed
that decreasing brain Se by genetic inactivation of SELENOP, or its
receptor, apolipoprotein E-receptor type II (ApoER2) [23,24], caused
spontaneous neurological impairment and degeneration. AD is closely
associated with protein misfolding [25,26], leading to the formation of
molecules that cause neuronal cell damage and synaptic dysfunction.
Oxidative stress is an important molecular mechanism implicated in AD
and other neurodegenerative conditions [27–29], hence the seleno-
proteins are potentially capable of counteracting AD development,
owing to their antioxidant properties.
There is an age-associated increase in gene expression of SELENOP
[30] which may indicate an increased demand for Se in the ageing
organism. Moreover, in AD [31] and other neurodegenerative states
[32], the SELENOP gene appears to be up-regulated even more. This
fact and the neurological phenotype of Selenop-knockout animals im-
plicate SELENOP in cognition and, in particular, give it a possible role
in AD. Interestingly, in the brain, SELENOP uses the same receptor as
apolipoprotein E (ApoE); ApoE polymorphisms are considered to be the
strongest genetic risk factor for AD [33,34]. The current review focuses
on the recent ﬁndings that suggest the involvement of SELENOP in AD
pathology, based on model and human studies. Although mainly posi-
tive aspects of SELENOP are featured in this review, we also comment
on the detrimental eﬀects of excessive Se supplementation or exposure,
including potential neurotoxicity, elevated risk of type II diabetes
mellitus (T2DM), certain malignancies and amyotrophic lateral
sclerosis (ALS) [35,36], with T2DM having SELENOP as a candidate
protein that mediates impaired insulin response [37–39].
2. Biochemistry and functions of SELENOP
SELENOP is a secreted heparin-binding glycoprotein [40], mainly
supplied to the blood by hepatocytes [12,41,42]. SELENOP is also
present in extra-hepatic tissues, most notably in the brain [43] and
testes [24]. Although SELENOP is a secreted protein, its intracellular
presence was reported for neurons [43], testicular Leydig cells [44],
adipocytes [45], and pancreatic β-cells [46]. SELENOP is the most
abundant selenoprotein [47] in cerebrospinal ﬂuid (CSF) which has
been shown to have a central role in brain-Se homeostasis [9]. SE-
LENOP may be produced by astrocytes, at least in vitro [40,48]. The
liver is a central regulator of body Se homeostasis, directing it to either
selenoprotein synthesis or towards excretion [19]; Fig. 1 depicts body
Se transport with SELENOP being the main Se-carrier to the brain.
However, additional Se transport to neuronal tissue may be attributed
to selenosugars [49] and/or other low molecular mass Se-species [47].
Selenoprotein biosynthesis is regulated by a highly sophisticated system
that operates at transcriptional, translational and post-translational le-
vels [2], depending on the availability of Se [50]. Interestingly, recent
in vitro experiments by Turanov et al. [17] have shown that cysteine
(Cys) may replace Sec in SELENOP under Se restriction, whereas nor-
mally in human blood plasma, up to 8% (average of 4%) of the Sec
residues in SELENOP are replaced by Cys. More details on selenoprotein
biosynthesis machinery and functions are available elsewhere
[5,19,51–55].
SELENOP has a signiﬁcant role in delivering Se to the brain by
binding to a surface receptor ApoER2, a member of the lipoprotein
receptor family, through clathrin-dependent endocytosis (Fig. 2) [58].
Mice that cannot synthesize SELENOP develop abnormal movements,
spasticity, and spontaneous seizures [59]. High amounts of SELENOP
are found in the brain [54,60,61]. Interestingly, the absence of SE-
LENOP (but not of selenocysteine lyase, the enzyme that retrieves Se
from the selenoproteins after proteolysis), has been found to result in
severe neurological dysfunction [62]. It seems that the central nervous
system (CNS) relies much more on an external Se supply rather than on
Se recycling. Thus, SELENOP is thought to play a signiﬁcant role in
neuronal survival but is also associated with AD pathology [60]. As-
trocytes appear to secrete SELENOP that neurons subsequently take up
via the ApoER2 [54]. Interestingly, for the kidney, the main tissue that
produces and secretes GPX3 [63], SELENOP uptake is not associated
Fig. 1. Body Se transport scheme [12,56,57]. Abbreviations: ApoER2 – apolipoprotein
receptor type II, GPX3 – glutathione peroxidase type III, GPX4 – glutathione peroxidase
type IV, Sec – selenocysteine, MeSec – methylselenocysteine, SELENOM – selenoprotein
M, SELENOP – selenoprotein P, SELENOS – selenoprotein S; *– auxiliary brain Se trans-
port mechanism, independent of SELENOP, possibly related to selenosugars [49] and
other low molecular mass Se-species [47].
Fig. 2. Clathrin-dependent endocytosis of SELENOP via ApoER2.
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with ApoER2 but with another lipoprotein receptor – megalin [64]
(Fig. 1).
ApoE has been shown to have a primary role in AD development
and progression [65] and it is now fully established that the ApoE-ε4
allele is a strong hereditary risk factor for AD [33]. Since ApoE shares
the same brain receptor as SELENOP, its mutations may aﬀect Se uptake
by the brain; however, to the best of our knowledge, there is, as yet, no
such direct evidence. Additionally, the Se species, selenate [66–68] and
selenomethionine [69] were reported to have an attenuating eﬀect on
tau hyperphosphorylation, which is characteristic of AD [70,71]. Thus,
Du et al. proposed that SELENOP might either provide Se to inhibit the
abnormal phosphorylation of tau-protein directly or to suppress ROS-
mediated tau phosphorylation [72]. The delivery hypothesis is to some
extent supported by the speciation ﬁndings of Michalke and Berthele
[73], later conﬁrmed by Solovyev et al. [47], that showed that selenate
was formed in the CSF as a degradation product of SELENOP and
probably of other selenoenzymes. It should be noted, however, that in
vitro observations of stored CSF are unlikely to reﬂect real brain bio-
chemistry.
The SELENOP-encoding gene is known to have several single nu-
cleotide polymorphisms (SNPs) [74] which are relevant to the protein
level and function [75,76]. Méplan et al. [75] performed SNP screening
in 20 individuals and reported two common SNPs related to G to A
substitution in SELENOP mRNA. The ﬁrst SNP corresponds to the amino
acid Ala to Thr replacement at the position 234 (Ala234Thr,
rs3877899). The second SNP is present in the 3′-untranslated region
(UTR) (rs7579) [77]. The authors carried out an intervention study (75
volunteers, 6-week supplementation with 100 µg Se/day, washout
period of 6 weeks) to evaluate the role of SELENOP gene polymorph-
isms in Se metabolism. A signiﬁcant alteration of plasma Se con-
centration and other Se-status biomarkers (plasma SELENOP, plasma
GPX3, erythrocyte thioredoxin reductase type I and lymphocyte GPX)
was found for individuals, carrying both rs3877899 and rs7579 SNPs of
SELENOP. The authors have suggested that the observed diﬀerences
may relate to altered post-translational modiﬁcation in the case of the
rs3877899 SNP, whereas rs7579 may inﬂuence SELENOP synthesis,
aﬀecting the SECIS region of mRNA. Interestingly, SELENOP SNPs were
shown to be associated with a change in the ratio of 50- to 60-kDa
SELENOP isoforms in blood plasma [77]. No eﬀect of rs3877899 and
rs7579 SNPs on Se status or oxidative stress parameters was found in a
Brazilian population with mild cognitive impairment (MCI) [76].
Originally, SELENOP neuroprotective functions were considered to
be limited to Se supply to the brain to produce primary antioxidant
selenoproteins, such as glutathione peroxidase (GPX)1 [78–80] and
GPX4 [81–83], methionine sulfoxide reductase B [84] and selenopro-
tein M (SELENOM) [85–87]. Another selenoprotein, selenoprotein S
(SELENOS), associated with the endoplasmic reticulum, also appears to
be capable of decreasing tau phosphorylation [88]. However, at present
the role of SELENOP in the brain is considered as more than just a Se-
carrier owing to its redox activity and eﬀective interactions with dif-
ferent bioactive molecules and metal ions.
Human SELENOP has two histidine-rich domains [17] which may
account for its capacity to bind to transition metals, e.g. copper (Cu) and
iron (Fe). These metals are implicated in neurodegenerative pathology,
including that of AD [29,89,90]. Indeed, some authors have ascribed
the neuroprotective properties of SELENOP to its metal-binding prop-
erties. The redox motifs (UXXC and CXXC) and the histidine-rich do-
main of SELENOP are known as bivalent cation-binders (e.g., of Cu2+
and Zn2+) [91].
3. SELENOP interaction with bioactive components involved in
Alzheimer's disease pathology
SELENOP, as a chemically active protein, containing multiple Sec
and cysteine residues, interacts with a number of substances that may
be related to brain pathology. First of all, its metal-binding capacities
are widely known [92,93]. Importantly, amyloid-β (Aβ) also has a
strong aﬃnity for metals, binding redox-active essential metals like Cu
[94–98] and Fe [97] as well as Zn [91,96,97,99,100], which may alter
Cu and Fe binding by protein homeostasis [7,26]. SELENOP also binds
to toxic metals such as cadmium (Cd) [99,101] and mercury (Hg)
[102]. Mis-compartmentalization of metals such as Cu, Zn, and Fe oc-
curs in the AD brain [88], causing detrimental neuronal outcomes
[103], though the total metal amount remains unchanged. Accordingly,
an attractive working hypothesis might be the formation of ternary
complexes between metal cations, Aβ and SELENOP. Such complexes
might perhaps be less toxic than Aβ-metal complexes alone, owing to
tight binding of redox-active ions by Sec residues of SELENOP and/or
its histidine-rich domain. However, since Aβ is presumably much more
abundant in the AD brain than SELENOP, the most important eﬀect
might be the binding of Se such that it is unavailable for normal in-
corporation into selenoproteins. Since Cu is found relatively abundantly
in Aβ [79] and Cu2+ binds very strongly to Sec residues, [89], a ternary
complex between Aβ, Cu2+, and SELENOP might be a plausible can-
didate for the co-localization with Aβ in AD brains. In particular, in
mice neuroblastoma N2A cells Cu+/Cu2+ promotes aggregation of tau
and increases its cytotoxicity, compared to tau alone [104]. This causes
a decrease of microtubule-associated protein 2 (MAP2) concentration,
mitochondrial density, and mobility. SELENOP was shown to suppress
and even reverse this process signiﬁcantly [104]. The decrease of MAP2
concentration leads to the dysfunction of the microtubule assembly and
therefore to the disturbance of cell shape and polarity. The eﬀect of
SELENOP on tau aggregation also maintains MAP2 which supports
neuronal signal transduction. SELENOP attenuates Cu-induced Aβ ag-
gregation, but the model aggregates diﬀer from those present in actual
AD-lesions by having a more amorphous structure. Additionally, the
induction of amyloid precursor protein (APP) pathological cleavage is
known to be promoted by Zn exposure and reversed by SELENOP [91].
Interestingly, SELENOP increases Aβ ﬁbrillization rate, while de-
creasing the total amount of ﬁbrillated Aβ. Studies with Selenop-
knockout murine neuroblastoma N2A cells have shown reduced viabi-
lity and increased apoptotic rate with exposure to Aβ oligomers [60].
Another interesting issue is the integration of SELENOP with mi-
crotubules and its involvement in cytoskeleton assembly and function.
The importance of SELENOP for neuronal transport functions was de-
monstrated by Valentine et al. [105]; in Selenop-knockout mice fed
with either Se-deﬁcient or Se-adequate diets, enlarged dystrophic axons
were observed in both groups. The axons were abnormally packed with
organelles, indicating the disruption of fast axonal transport induced by
dysfunction of the microtubule apparatus. Finally, acting as a Se source,
SELENOP may contribute to microtubule dynamics, since other sele-
noproteins appear to be involved in the maintenance of microtubule
stability. For instance, the depletion of 15 kDa selenoprotein (SE-
LENOF) in T-Rex-HeLa and Chang liver cells led to cytoskeleton ab-
normalities, namely blebbing and shift of α-tubulin and F-actin locali-
zation [106]. In Selenof-knockouts, F-actin was mislocated in the
cytoplasm and bleb membranes, whereas the presence of α-tubulin was
observed near nuclear and bleb membranes. The changes in tubulin and
actin localization led to the disturbance of normal cytoskeletal structure
and intracellular transport. In brain cells, analogous disturbances might
be induced by the depletion of SELENOP, resulting in the decreased
production of SELENOF and other selenoproteins.
The role of SELENOP in cytoskeleton assembly was reported as an
interaction between SELENOP and the C-terminus domain of human α-
tubulin [72]. The study was conducted with an isolated domain and
may not represent the actual interaction between SELENOP and mi-
crotubules. Interestingly, the C-terminal domain of α-tubulin is asso-
ciated with the regulation of microtubule assembly and can interact
with cationic entities, such as tau-protein, Ca2+, and polyamines [107].
Direct binding of SELENOP or other selenoproteins with full cytoske-
leton components has not been reported, to the best of our knowledge.
Additionally, since SELENOP is mainly present in extracellular space,
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the indirect relation of SELENOP with cytoskeleton via Se delivery to
the cells seems more likely. According to Du et al., the association of
SELENOP and α-tubulin might imply that SELENOP has a role in reg-
ulating the dynamics of microtubules; this is crucial for intracellular
transport and the maintenance of cell polarity [72].
We hypothesize that the interaction between SELENOP and α-tu-
bulin may contribute to AD pathology, aﬀecting tau-protein phos-
phorylation and the formation of neuroﬁbrillary tangles. The in vitro
studies discussed in this section need to be supported by in vivo and
human-based experiments which are lacking at present.
4. In vivo and ex vivo studies
Most of the evidence implicating SELENOP in neurodegeneration
pathology and etiology is based upon murine transgenic studies.
Selenop is one of three murine selenoprotein genes, which along with
GPX4 and selenoprotein W (SELENOW), has a high level of expression
in over 90% of murine brain regions, including the olfactory area,
Table 1
Human studies on Se supplementation and/or status in AD. The studies which were already considered in Loef et al. [15] are not separately summarised.
Study design Se assessed/ administered Baseline Se Comment Reference
Meta-analysis of Se in AD: 9
placebo-controlled trials,4
prospective,4 cross-sectional,
and 15 case-control studies.
Diﬀerent doses from 100 µg Se
(form unspeciﬁed) to 1720 µg
(as selenite)
N/A This review summarizes most of the
studies from 1986 to 2010.
Loef et al. 2011 [15]
EVA longitudinal cohort study of Se
in cognitive impairment in
1166 subjects aged 60–70
(initial report)b
Baseline plasma Se N/A Signiﬁcantly increased risk of
cognitive decline over a four-year
period in those with plasma
Se<75.8 µg/L at baseline (OR 1.58;
95% CI 1.08–2.31).
Berr et al. 2000 [128]
EVA longitudinal cohort study of Se
in cognitive impairment in
1166 subjects aged 60–70 (ﬁnal
reports)
Measurement of plasma Se
over a 9-year period
Baseline plasma Se
(µg/L) 82.9±15.8
Cognitive decline was signiﬁcantly
associated with the magnitude of
plasma Se decrease (from
82.9± 15.8–75.8± 16.6 µg/L) over a
9-year period.
Akbaraly et al. 2007
[131]; Berr et al. 2012
[129]
Cross-sectional study of the
relationship between ﬁngernail
Se and cognitive performance
in 2000 rural Chinese, aged ≥
65 y.
Finger-nail Se concentration Estimated Se intake
19–47 µg/day
Lower nail Se corresponded to lower
cognitive-test performance.
Gao et al. 2007 [132]
Case-control study of 28 CE cases vs.
29 controls, aged 60–89.
Se measured in plasma,
erythrocytes, nails, and diet
N/A Se concentration greater in controls
than in AD cases, i.e. AD vs. control:
plasma 32.6± 22.0 vs. 51.0±21.1
μg/L (P< 0.005); erythrocytes
43.7± 23.0 vs. 79.2± 46.4 μg/L
(P< 0.005); nails 0.30± 0.14 vs.
0.40± 0.13 μg/g (P<0.005).
Cardoso et al. 2010 [133]
Case-control study: 27 CE
patients (age 80.6± 5.7), 17
MCI patients (age 77.7± 5.3),
28 controls (age 71.2±6.2)
Plasma and erythrocyte Se
concentration
N/A Erythrocyte Se decreased with
cognitive function and was lower in
the AD group than in controls
(43.73± 23.02 vs. 79.15± 46.37 μg/
L; p=0.001). The AD group exhibited
the lowest plasma Se (34.49± 19.94
vs. MCI 61.36± 16.08, vs. controls
50.99±21.06 μg/L).
Cardoso et al. 2014 [134]
Case-control study of Se
concentration in serum, CSF,
and erythrocytes of AD, MCI
and control subjects (AIBL
study).
Se concentration in
erythrocytes CSF and serum
N/A Se concentration in erythrocytes from
AD group was signiﬁcantly lower than
that in the control group (68.4± 5.1
vs. 92.2± 6.6 µg/L; P<0.001).
Cardoso et al. 2017 [135]
Serum or CFS Se concentration in AD
or MCI patients and healthy controls
did not diﬀer.
Case control study: 173 CE patients
(age 52–87), 85 CE patients
with vascular dementia
symptoms, 54 controls.
Se assessed in plasma and CSFb N/A Plasma Se diﬀered between AD and
controls (P<0.05): median 86, 87
and 99 µg/L for AD, AD with vascular
components and controls,
respectively; no diﬀerence between
CSF concentrations.
Gerhardsson et al. 2008
[140]
Case-control study: 264 CE patients
vs. 54 controls
Plasma and CSF Se
concentration measured ratio
calculated
No values given No diﬀerence found in plasma/CSF Se
ratio between AD patients and
controls.
Gerhardsson et al. 2011
[141]
PREADViSE recruited 7540 men
mean age 67.5 (5.3) y to an RCT
of Se, or vitamin E, or both, or
placebo. After 7 y, the trial was
converted to cohort study; 3786
men continued into the cohort
study. Dementia cases were
identiﬁed.
Four treatment groups: Se
(200 μg/d), or vitamin E (400
IU/d), or both, or placebo. No
measurement of Se status.
Not disclosed. However,
baseline serum Se
concentration in the
parent SELECT study
was 135 µg/L [142]
No positive eﬀect of Se on the
development of dementia. The
intervention was stopped along with
the parent trial, but the study
continued as observational. Dementia
incidence (4.4%) did not diﬀer
between the study arms: HR (95% CI)
0.88 (0.64–1.20) for vitamin E, 0.83
(0.60–1.13) for Se, and 1.00
(0.75–1.35) for the combination, vs.
placebo.
Kryscio et al. 2017 [143]
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hippocampus, isocortex, and cerebellar cortex [108]. Interestingly,
GPX4, the only GPX form required for proper embryogenesis [82], was
recently reported to require Se, as Sec, speciﬁcally for postnatal de-
velopment, preventing fatal epileptic seizures [83]. At the same time,
the activity of mutant Cys-GPX4 is suﬃcient for the normal embryonic
development [83].
All mice brain regions have been shown to be highly dependent on
SELENOP for maintenance of the Se level in the brain [109]; knockout
of ApoER2 or Selenop, along with neuron-speciﬁc ablation of seleno-
protein biosynthesis, caused neurological dysfunction [54,62,110,111].
Within 12 days, Selenop-knockout mice (Selenop-/-), fed with a Se-de-
ﬁcient diet showed degeneration in the majority of brain regions [111].
Importantly, the brainstem and thalamus suﬀered most from SELENOP
depletion, resulting in impaired motor function [110]. Additionally,
neuronal loss was observed in the somatosensory cortex and lateral
striatum [111], while there was signiﬁcant impairment in hippo-
campus-dependent learning [112]. The observed eﬀects were attributed
to the neuronal and axonal loss and changes in the morphology of
hippocampal cells [111]. Increasing brain Se by raising Se intake re-
duced the degeneration [23,113]. γ-aminobutyric acidergic (GA-
BAergic) parvalbumin-positive interneurons appear to be the most
susceptible to SELENOP deletion [114]. These neurons participate in
neural activity synchronization and have already been shown to be
highly sensitive to oxidative damage [115–117]. The degeneration of
these parvalbumin-positive interneurons seems to be the reason for the
epileptiform phenotype in Selenop-/- animals [118]. ApoER2-mediated
uptake of SELENOP (Fig. 2) appears to be a major neuroprotective
mechanism for these neurons [13,114]. Finally, a comparison study of
brain selenoprotein expression in the wild-type and Selenop-knockout
mice showed considerably reduced expression of GPX4, selenoproteins
K, M, W, and other selenoproteins in the latter [119]. Thus, it may be
concluded that the deletion of SELENOP, and presumably Se deﬁciency,
induce neuronal and axonal degeneration in addition to neuronal
changes in the developing human brain [111], resulting in motor dys-
function and behavioral phenotype [110,112]. On the other hand, a Se-
rich diet improves the state of both Selenop-knockouts [113] and epi-
leptic patients [120,121], so there must be routes of Se delivery to the
CNS, independent of SELENOP-mediated uptake.
Astrocytes, which are less sensitive than neurons to oxidative stress
[122], increase the production of antioxidant selenoproteins upon brain
injury [54]. The hypothesis, derived from the observations reviewed
here, is that SELENOP has a protective role in the brain. Finally, an-
other possible eﬀect of Se and selenoproteins on the neurodegenerative
processes may be related to their immunological activity. Inﬂammation
is involved in AD pathology [123], and Se is known to aﬀect NF-κB and
AP-1 associated pathways [124,125].
5. Human studies linking Se exposure or supplementation to
neurodegeneration
Since the central hypothesis that SELENOP has a role in AD and,
more generally, in brain disorders, is linked to the delivery of Se to
brain tissue for selenoprotein synthesis, we will examine the epide-
miological evidence linking Se exposure/supplementation to neurode-
generation [6,15,34,126,127]. Observational epidemiological studies
have shown that higher Se status beneﬁts neurological function and
cognitive performance. In the French EVA cohort of 1166 people aged
60–70 years [128], a signiﬁcantly elevated risk of cognitive decline was
observed in those with low plasma Se (Table 1) at baseline [129],
though other studies reported the absence of such an association [130].
Additionally, cognitive function correlated with the degree of decrease
in plasma-Se concentration over a nine-year period [131]. A cross-
sectional study (2003–2005) of 2000 adults (≥ 65 y) from four rural
sites in two provinces of China, reported a strong association between
nail Se concentration (Table 1) and performance in cognitive tests
[132]. This is in agreement with the ﬁndings of a set of small studies by
Cardoso et al. [133–135], who reported (i) lower levels of plasma and
erythrocyte Se concentrations in patients with AD and MCI, (ii) de-
creased levels of Se in plasma and erythrocytes of AD patients vs.
matched controls from São Paulo, Brazil and, (iii) a decreased con-
centration (p < 0.05) of Se in erythrocytes of AD patients than in
healthy controls (28 cases vs. 29 controls) [135], though no diﬀerence
was observed for total Se in serum or CSF. It needs to be mentioned that
in the context of cognitive function in older adults, low plasma Se may
result from reduced production of secreted GPX3 and particularly of
SELENOP caused by inﬂammatory cytokines during the acute-phase
response [136]. On the other hand, systemic inﬂammation in AD pa-
tients [97,137] may cause decreased circulating Se concentration.
Correspondingly, a state of chronic inﬂammation was shown to cause
decreased Se status [138,139]. It is worth mentioning, though, that
improved cognition in the elderly and AD should probably not be
considered as direct opposites, since the age-associated decline in
cognition lacks the characteristic pathologic events present in AD. This
should be considered when evaluating the results of EVA [131] and
similar studies [132]. As for the small studies of Cardoso et al.
[133–135], these may lack statistical power to be conclusive.
Gerhardsson et al. [140] reported altered Se levels in blood plasma
of patients with AD, but a later study by the same research group
showed no diﬀerence in Se CSF/blood plasma ratios between AD pa-
tients and healthy controls [141]. Additionally, in Indian cohorts of AD
and vascular-dementia patients, blood Se was no diﬀerent than in sex-
and age-matched controls [144]. Furthermore, blood Se did not corre-
late with the activity of GPX, thioredoxin reductase, plasma Aβ42,
plasma tau and tau-to-Aβ42 ratio. Interestingly, human genetic studies
also point to the protective role of selenoproteins, showing that muta-
tions in Sec synthesis machinery cause progressive cerebellocerebral
atrophy (PCCA) neurological impairment. The phenotype, which com-
prises non-dysmorphic, profound mental retardation is often accom-
panied by myoclonic or generalized tonic-clonic seizures [125,145].
Importantly, PCCA syndrome somewhat resembles the Selenop-
knockout phenotype of transgenic animals [146]. SELENOP-deﬁcient
mice develop hyperexcitability and seizures [147], similar to childhood
epilepsy patients who are Se deﬁcient [148,149].
Nevertheless, some observational studies considered certain Se
species as potential risk factors for neurodegeneration. Vinceti et al.
reported that higher levels of SELENOP in CSF were associated with a
lower risk of sporadic amyotrophic lateral sclerosis (ALS), while a
higher risk of neurodegeneration was associated with elevated selenite
in CSF [35]. A further cohort study including ALS patients with disease-
associated mutations (C9ORF72, SOD1, FUS, TARDBP, ATXN2, and
TUBA4A) has reported elevated levels of inorganic Se (selenite and
selenate), GPX and SELENOP in a patient with the tubulin-related
TUBA4A mutation, whereas in the remaining ALS individuals, elevated
selenomethionine was observed [36]. Finally, in a recently published
study, the increased risk (adjusted hazard ratio of 3.1, 95% conﬁdence
interval 1.0–9.5) of developing AD later in life was observed in MCI
patients with increased concentration of the potentially toxic inorganic
selenium species, selenate, Se(VI), in CSF [150]. The study was con-
ducted in 56 MCI patients; the development of AD was monitored after
a median follow-up of 42 months.
Notably, a 2011 meta-analysis of observational studies, cohort stu-
dies and placebo-controlled trials investigating the association between
cognitive decline and Se supplementation found no evidence for a role
of Se in the treatment of AD [15]. Table 1 presents the studies that were
not included in the meta-analysis.
The most recent placebo-controlled, randomized clinical trial (RCT),
PREADVISE, that ended in 2015 showed no eﬀect of Se supplementa-
tion on AD risk in elderly males [143]. This extensive study (7540
participants, mean age 67, 2002–2015) was run as an ancillary study of
the Selenium and Vitamin E Cancer Prevention Trial (SELECT) [142].
When the SELECT was stopped in 2009 owing to an interim analysis
that showed a lack of a beneﬁcial eﬀect on prostate cancer [142],
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PREADVISE was continued as a cohort study [151]. PREADVISE
showed a lack of eﬀect of both Se and vitamin E on dementia risk-
adjusted hazard ratios (95% CI), were 0.83 (0.60–1.13), 0.88
(0.64–1.20) and 1.00 (0.75–1.35) for selenium, vitamin E, and (sele-
nium + vitamin E), respectively. However, the lack of eﬀect of Se
supplementation in the PREADVISE cohort is hardly surprising
[152–154], given the high baseline Se status of the participants in the
parent SELECT, where baseline serum Se concentration was 136 µg/L
[142]. At such a baseline serum Se concentration, SELENOP, and
probably all selenoproteins would already have attained a plateau of
concentration or activity, precluding any further beneﬁt from addi-
tional Se [155].
A role of Se in seizures, coordination, and Parkinson's disease (PD)
[126] has been investigated in a number of studies. The InChianti study
of coordination performance in elderly participants (n= 1012, age
≥ 65 y) found poorer performance-based coordination results in in-
dividuals with lower plasma Se than in those with higher concentra-
tions, though the authors reported no association with PD morbidity,
rigidity, rest-tremor, or the number of postural abnormalities [156].
However, the investigators noted a signiﬁcant trend towards increased
prevalence of PD in the lower Se quartiles. Other studies have reported
signiﬁcantly lower serum Se concentration in children and adults with
epileptic seizures [120] and in children with febrile seizures [157].
Although a number of human studies have addressed the possible
role of Se supplementation in preventing cognitive decline or AD, the
data are still inconclusive. The reason for inconsistencies between dif-
ferent studies may be related to confounding bias, diﬀerences in eva-
luation of dementia and cognitive performance, inadequate controls,
unspeciﬁed initial Se status and speciation, so only a fraction of the
studies may be described as ‘high quality’ [34,158].
6. Potential mechanisms for the eﬀect of SELENOP in Alzheimer's
disease
The ApoE-ε4 allele is a well-known genetic risk factor for the late-
onset sporadic AD in most populations [159]. The mechanism by which
ApoE-ε4 increases the risk of AD is still to be characterized. For other
alleles of ApoE, ApoE-ε3 and in particular ApoE-ε2, there is an enhanced
proteolytic breakdown of Aβ, both intra- and extracellularly, so the
increased vulnerability to the AD pathologic changes may be attributed
to relative ineﬀectiveness of the ApoE-ε4 isoform to inhibit
amyloidogenesis. It is therefore of considerable interest that the
ApoER2 is responsible for uptake of Se, as SELENOP, in neurons. Thus,
SELENOP may have a crucial neuroprotective role that prevents
apoptosis and increases neuronal survival by mitigating the Aβ-induced
oxidative challenge [60].
The expression of SELENOP in postmortem brains from patients
with conﬁrmed AD pathology and control tissue from healthy in-
dividuals was compared [41]. It was found that SELENOP im-
munoreactivity colocalized with Aβ plaques and neuroﬁbrillary tangles
[107,160]. Other non-diﬀuse and dense-core Aβ lesions were frequently
associated with SELENOP immunopositive cells. A signiﬁcant associa-
tion between Aβ plaques and SELENOP, along with multiple cells im-
munoreactive to SELENOP, was observed. Bellinger et al. [107] showed
a strong link between SELENOP and hallmarks of AD (Aβ plaques and
neuroﬁbrillary tangles). These postmortem studies additionally indicate
the intracellular presence of SELENOP, which is conﬁrmed by other
studies [43]. SELENOP up-regulation may relate to its antioxidant
properties or increased Se requirement in AD neuronal tissue. More-
over, SELENOP binding to Aβ and neuroﬁbrillary tangles may sequester
Se, reducing Se supply to neurons and glial cells, thereby promoting
oxidative stress. This is in agreement with the in vitro data of Takemoto
et al. [60], who reported higher Aβ toxicity in Selenop-knockout mice
neuroblastoma cells than in wild-type cells.
In a recent study, the AD brain was shown to increase the release of
SELENOP from the choroid plexus to the CSF [160]. Rueli et al. [160]
related the increase in expression of SELENOP in the choroid plexus and
its increased secretion to excessive reactive oxygen species, cellular
stress, and inﬂammation, caused by AD changes in the brain. Post-
mortem studies by Bellinger et al. [61,81] in the PD brain also showed
altered GPX4 and SELENOP expression. SELENOP was reduced in the
substantia nigra of PD brains but with a relative increase compared to
the total number of nigral cells. Importantly, SELENOP localized in
Lewy bodies, i.e. the PD brain lesions [61]. These ﬁndings may be at-
tributed to the compensatory response in SELENOP expression towards
oxidative stress associated with neurodegeneration. However, some
additional mechanisms may be involved; for instance, the studies in
postmortem PD brains showed that SELENOP presumably had its sig-
naling function in the dopaminergic synapses through direct interaction
with ApoER2 [61]. Research has shown that ApoER2, which is known
to have postsynaptic localization [161], is associated with glutama-
tergic N-methyl-D-aspartate (NMDA) receptors [162], which are
Fig. 3. A summary of the ﬁndings on SELENOP in AD. The
scheme illustrates the body of research connecting studies on AD
and selenium with a focus on SELENOP. The smaller boxes in-
dicate the primary processes or components of interest in the
studies performed. Larger boxes summarize relevant domains –
genetic, epidemiology, in vitro, and in vivo studies. The arrows
demonstrate the interactions within and between the domains,
leading to new hypotheses and study designs.
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probably involved in AD pathology. These observations suggest that
there may be some form of interaction between SELENOP and Aβ,
leading to complex formation. It should be emphasized though, that
increased expression of SELENOP and its presence within AD brain le-
sions does not necessarily imply a positive eﬀect against AD progression
[163]. Elevated SELENOP may be just a bystander associated with
redox stress or may take part in the detrimental processes in the AD
brain. This issue demands further exploration. Additionally, since SE-
LENOP is mainly an extracellular protein, the results of certain in vitro
studies on SELENOP interaction with intracellularly localized proteins
(e.g. α-tubulin, tau-protein etc.) and even on interaction with Aβ and
metal ions should be treated with caution since they may not occur in
the real brain environment at actual concentrations of SELENOP and its
counterparts. Finally, the results of postmortem studies may be biased
by tissue decay, lifetime drug treatment, and/or tissue preparation.
In accordance with the metal dysregulation hypothesis, it is
tempting to consider that AD treatment or prevention strategies might
include optimizing Se intake [127]. The selenoprotein family is crucial
for normal brain function, and SELENOP is among the selenoproteins of
importance. Fig. 3 summarizes current knowledge of the role of SE-
LENOP in AD. In our opinion, further studies should more directly
address the issue of optimal Se supply, relevant biomarkers of Se status
and optimal reference ranges [126]. For instance, some authors con-
sider plasma/serum or nail Se as mainly Se exposure markers, not re-
ﬂecting the body's selenoprotein machinery and Se speciation in gen-
eral [158]. Aside from purely analytical complications related to the
measurement itself, the activity or concentration of SELENOP and GPX3
are also being questioned as relevant markers, since in this case the
terms ‘optimal’ or ‘optimized’ expression/activity [164] is often sub-
stituted by ‘maximal’ or ‘maximized’ [163], which is probably not ap-
propriate for all populations and health conditions. Although the issue
of markers and optimal intake range has been discussed since the early
days of selenobiology, they seem unclear even today and probably
depend on the health eﬀect being discussed.
7. Conclusion and perspectives
SELENOP, as a central selenoprotein underpinning body Se hier-
archy and brain Se homeostasis, has an important role in the body.
Research shows that SELENOP aﬀects Aβ and hyperphosphorylated tau
aggregation and toxicity in addition to interacting with redox-active
metals in the brain, such as Cu, Fe, and Hg. It is capable of antioxidant
enzyme activity and appears to possess signaling functions via neuronal
ApoER2. As the Se-transport protein, it provides Se to neurons and glial
cells to synthesize antioxidant selenoproteins that mediate the redox-
stress response. Nevertheless, certain roles of SELENOP in brain func-
tion still require clariﬁcation, e.g., its involvement in glial activation,
and its relation to certain ‘healthy’ and pathological signaling pathways
in neuronal and glial tissue, including its roles in neuronal calcium
homeostasis/excitotoxicity.
Human studies need to pay more attention to Se status; there is no
rationale for giving supplemental Se to population groups where Se
status is already adequate and SELENOP concentration, and probably
that of other selenoproteins, has reached its maximum. Indeed, this was
the case in the only large randomized, controlled trial to date
(PREADViSE) that attempted to investigate the eﬀect of Se supple-
mentation on AD risk in elderly males and, unsurprisingly, found no
eﬀect [143]. Symptoms of Se toxicity (alopecia and dermatitis) were in
fact shown in SELECT, the parent study of PREADViSE [142], sug-
gesting that the dose that was given had adverse eﬀects in this popu-
lation that already had quite a high Se status. Hence this outcome is not
relevant to Se-deﬁcient populations. It needs to be appreciated that the
relationship between Se intake and status is not linear, but approx-
imates more closely to a U-shape where adverse eﬀects (e.g. on mor-
tality and prostate cancer) are found both at low and high Se intake/
status [4,165–167]. The majority of neurological studies to date point
to a neuroprotective eﬀect of SELENOP against cognitive decline and,
possibly, AD. Any further RCTs in this domain, if carried out in popu-
lations of appropriately low Se status (e.g. in European populations)
may lead to novel strategies for treatment and prevention of dementia.
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